Myofiber-type-dependent ‘boulder’ or ‘multitudinous pebble’ formations across distinct amylopectinoses-Reference-Cited by-同舟云学术

Myofiber-type-dependent ‘boulder’ or ‘multitudinous pebble’ formations across distinct amylopectinoses

Published:2024-02-27 Issue:1 Volume:147 Page:
ISSN:0001-6322
Container-title:Acta Neuropathologica
language:en
Short-container-title:Acta Neuropathol

Author:

Mitra Sharmistha,Chen Baozhi,Shelton John M.,Nitschke Silvia,Wu Jun,Covington Lindsay,Dear Mathew,Lynn Tori,Verma Mayank,Nitschke Felix,Fuseya Yasuhiro,Iwai Kazuhiro,Evers Bret M.,Minassian Berge A.^ORCID

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

Japan Society for the Promotion of Science

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00401-024-02698-x.pdf

Reference127 articles.

1. Aboujaoude A, Minassian B, Mitra S (2021) LUBAC: a new player in polyglucosan body disease. Biochem Soc Trans 49:2443–2454. https://doi.org/10.1042/BST20210838

2. Aguado C, Sarkar S, Korolchuk VI, Criado O, Vernia S, Boya P et al (2010) Laforin, the most common protein mutated in Lafora disease, regulates autophagy. Hum Mol Genet 19:2867–2876. https://doi.org/10.1093/hmg/ddq190

3. Ahonen S, Nitschke S, Grossman TR, Kordasiewicz H, Wang P, Zhao X et al (2021) Gys1 antisense therapy rescues neuropathological bases of murine Lafora disease. Brain 144:2985–2993. https://doi.org/10.1093/brain/awab194

4. Akman HO, Sheiko T, Tay SK, Finegold MJ, Dimauro S, Craigen WJ (2011) Generation of a novel mouse model that recapitulates early and adult onset glycogenosis type IV. Hum Mol Genet 20:4430–4439. https://doi.org/10.1093/hmg/ddr371

5. Auge E, Duran J, Guinovart JJ, Pelegri C, Vilaplana J (2018) Exploring the elusive composition of corpora amylacea of human brain. Sci Rep 8:13525. https://doi.org/10.1038/s41598-018-31766-y

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neurological glycogen storage diseases and emerging therapeutics;Neurotherapeutics;2024-09